Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Inclusion Criteria:

• Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab,bevacizumab, trastuzumab, durvalumab or atezolizumab.

• 18 years and older.

• No known history of increased susceptibility to immunological reactions.

• Subject is able and willing to sign the Informed Consent Form prior to screeningevaluations.

Exclusion Criteria:

• Other research medication within 4 weeks of the start of the study.

• Inclusion in medical research in which the administration of medication shouldfollow its stated times and dosages of infusions

• Dosage deviates from standard protocol

• Patients whom receive drugs through a central venous catheter (and for exampleporth-a-cath).